JP2023547978A5 - - Google Patents
Info
- Publication number
- JP2023547978A5 JP2023547978A5 JP2023510318A JP2023510318A JP2023547978A5 JP 2023547978 A5 JP2023547978 A5 JP 2023547978A5 JP 2023510318 A JP2023510318 A JP 2023510318A JP 2023510318 A JP2023510318 A JP 2023510318A JP 2023547978 A5 JP2023547978 A5 JP 2023547978A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated polypeptide
- polypeptide according
- antigen
- cleavable linker
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025078945A JP2025131591A (ja) | 2020-08-11 | 2025-05-09 | 切断可能リンカー組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063064268P | 2020-08-11 | 2020-08-11 | |
| US63/064,268 | 2020-08-11 | ||
| PCT/US2021/045395 WO2022035866A1 (en) | 2020-08-11 | 2021-08-10 | Cleavable linker compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025078945A Division JP2025131591A (ja) | 2020-08-11 | 2025-05-09 | 切断可能リンカー組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023547978A JP2023547978A (ja) | 2023-11-15 |
| JP2023547978A5 true JP2023547978A5 (enExample) | 2024-08-07 |
| JP7681681B2 JP7681681B2 (ja) | 2025-05-22 |
Family
ID=80223911
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023510318A Active JP7681681B2 (ja) | 2020-08-11 | 2021-08-10 | 切断可能リンカー組成物および方法 |
| JP2025078945A Pending JP2025131591A (ja) | 2020-08-11 | 2025-05-09 | 切断可能リンカー組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025078945A Pending JP2025131591A (ja) | 2020-08-11 | 2025-05-09 | 切断可能リンカー組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11512113B2 (enExample) |
| EP (2) | EP4631977A3 (enExample) |
| JP (2) | JP7681681B2 (enExample) |
| KR (2) | KR20260042619A (enExample) |
| CN (1) | CN116348597A (enExample) |
| AU (1) | AU2026200907A1 (enExample) |
| CA (1) | CA3187754A1 (enExample) |
| ES (1) | ES3040950T3 (enExample) |
| MX (1) | MX2023001788A (enExample) |
| WO (1) | WO2022035866A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3694885A1 (en) * | 2017-10-14 | 2020-08-19 | CytomX Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| US12534734B2 (en) * | 2018-05-15 | 2026-01-27 | Drive Therapeutics Llc | Stem-loop compositions and methods for inhibiting interleukin-8 |
| MX2023013382A (es) | 2020-04-04 | 2024-01-30 | Janux Therapeutics Inc | Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras. |
| EP4631977A3 (en) | 2020-08-11 | 2025-12-10 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| AU2023226005A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| WO2024100451A2 (en) * | 2022-11-11 | 2024-05-16 | Janux Therapeutics, Inc. | Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens |
| US20240376170A1 (en) | 2023-01-11 | 2024-11-14 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025114529A1 (en) | 2023-12-01 | 2025-06-05 | Ablynx Nv | Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety |
| WO2025201560A1 (en) * | 2024-03-29 | 2025-10-02 | Vibrant Pharma Limited | Multispecific antigen-binding proteins and uses thereof |
| GB2641580A (en) * | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US20010031264A1 (en) | 1996-01-25 | 2001-10-18 | Andrew Segal | Vaccine compositions and methods of modulating immune responses |
| CA2654794A1 (en) | 2006-06-14 | 2007-12-21 | Imclone Systems Incorporated | Lyophilized formulations of anti-egfr antibodies |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
| CN110078827A (zh) | 2012-04-27 | 2019-08-02 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
| US9562110B2 (en) | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| US9562073B2 (en) | 2014-01-31 | 2017-02-07 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| MX2017006016A (es) * | 2014-11-11 | 2017-06-19 | Amunix Operating Inc | Composiciones conjugadas de xten direccionadas y metodos para producir las mismas. |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| BR112017023862A2 (pt) | 2015-05-04 | 2018-07-17 | Cytomx Therapeutics Inc | anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| MY200695A (en) | 2016-11-03 | 2024-01-11 | Bristol Myers Squibb Co | Activatable anti-ctla-4 antibodies and uses thereof |
| EP3694885A1 (en) | 2017-10-14 | 2020-08-19 | CytomX Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| JP2021518603A (ja) | 2018-03-20 | 2021-08-02 | シートムエックス セラピューティクス，インコーポレイテッド | 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法 |
| WO2019222282A1 (en) * | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
| US20220002370A1 (en) * | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| CA3120327A1 (en) * | 2018-12-06 | 2020-06-11 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| JP2022535924A (ja) | 2019-06-06 | 2022-08-10 | ジャナックス セラピューティクス，インク． | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
| CA3143519A1 (en) | 2019-06-26 | 2020-12-30 | Volker Schellenberger | Cd3 antigen binding fragments and compositions comprising same |
| EP4631977A3 (en) * | 2020-08-11 | 2025-12-10 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
-
2021
- 2021-08-10 EP EP25185336.2A patent/EP4631977A3/en active Pending
- 2021-08-10 KR KR1020267008789A patent/KR20260042619A/ko active Pending
- 2021-08-10 ES ES21856576T patent/ES3040950T3/es active Active
- 2021-08-10 US US17/398,500 patent/US11512113B2/en active Active
- 2021-08-10 MX MX2023001788A patent/MX2023001788A/es unknown
- 2021-08-10 EP EP21856576.0A patent/EP4196488B1/en active Active
- 2021-08-10 CN CN202180069665.6A patent/CN116348597A/zh active Pending
- 2021-08-10 JP JP2023510318A patent/JP7681681B2/ja active Active
- 2021-08-10 CA CA3187754A patent/CA3187754A1/en active Pending
- 2021-08-10 KR KR1020237008265A patent/KR102944047B1/ko active Active
- 2021-08-10 WO PCT/US2021/045395 patent/WO2022035866A1/en not_active Ceased
-
2022
- 2022-10-24 US US17/972,348 patent/US20230147782A1/en not_active Abandoned
-
2024
- 2024-09-19 US US18/890,543 patent/US20250019403A1/en not_active Abandoned
-
2025
- 2025-05-09 JP JP2025078945A patent/JP2025131591A/ja active Pending
-
2026
- 2026-02-09 AU AU2026200907A patent/AU2026200907A1/en active Pending